Top Ten articles in the Pharma Industry this week
pharmafile | September 16, 2016 | News story | Medical Communications | Bayer, GSK, Gilead, GlaxoSmithKline, J&J, JJ, Pfizer, Roche, Sanofi, Takeda, aspen, google, monsanto
As we come to the end of another week, we’re looking back at an exciting week in the industry; there has been some big industry team-ups and exciting acqusitions, and we finally got to see the end of a saga that we’ve been covering with bated breath for weeks and months!
10. GSK and J&J file rheumatoid arthritis treatment sirukumab in EU
Partnership seeks EMA approval to oust rival products from Roche and Sanofi.
9. Gilead appoints former Roche executive
Firm hires Rogers Luo as vice president and general manager of commercial operations in China.
8. Takeda forms “first of its kind” developmental partnership with CRO
The team-up will see the transfer of 300 staffers to PRA Health Services in order to deliver on development of its pipeline.
7. Pfizer launches legal action to block Xeljanz copies in India
US firm files pre-emptive lawsuits against Sun Pharma and Zydus Cadila to protect its rheumatoid arthritis patent.
6. GSK sells anaesthetic portfolio to Aspen for up to $372 million
South African group also secures remainder of the UK giant’s thrombosis portfolio.
5. Roche’s Ocrevus more effective than Merck’s Rebif, company claims
New data shows that Ocrevus was up to 75% more effective in reducing disease activity compared with rival Merck’s Rebif.
4. Feature: Clinical Trial Transparency
Sean Murray takes a look at how companies are coming to terms with expectations around transparency in clinical trials, and how pharma can benefit from a more inclusive approach going forward.
3. Bayer ponders $1.1 billion portfolio sale to fund Monsanto acquisition
German drugmaker brings in financial services firm JPMorgan Chase to help assess its options regarding the sale of its dermatology unit as it continues to secure the agricultural firm.
2. Bayer acquires Monsanto in largest-ever deal by a German company
The agreement comes at the end of weeks and months of relentless negotiations.
1. Sanofi and Google forge $500 million diabetes partnership
French drugmaker joins forces with Alphabet’s life sciences firm Verily to develop diabetes solutions.
Related Content
GSK shares results from phase 3 trial for gonorrhoea treatment
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …
GSK’s meningococcal vaccine candidate accepted for FDA review
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
